Biologic treatment outcomes in refractory eosinophilic fasciitis: A systematic review of published reports
- PMID: 33812957
- DOI: 10.1016/j.jaad.2021.03.089
Biologic treatment outcomes in refractory eosinophilic fasciitis: A systematic review of published reports
Conflict of interest statement
Conflicts of interest Dr. Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Authors Mufti, Kashetsky, Abduelmula, Lytvyn, and Sachdeva have no conflicts of interest to declare.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
